PRETORIA, South Africa, Aug. 1, 2017 /PRNewswire/ -- Xavant Technology (Pty) Ltd today announced that the U.S. Food and Drug Administration (FDA) cleared their Stimpod NMS460. With the U.S. patent ...

The Stimpod NMS460 includes a nerve-mapping pen-like probe which allows practitioners to locate nerves and evaluate the treatment progress. Xavant Technology announced that their non-invasive ...

The US Food and Drug Administration (FDA) has cleared a noninvasive neuromodulation device (Stimpod NMS460, Xavant Technology) for the relief of chronic intractable pain, the company has announced.

Xavant Technology is set to start selling its neuromodulation device for the treatment of pain in the U.S. through Bell Medical. The move follows the receipt of 510(k) clearance from the FDA, which ...

Xavant Technology (Pty) Ltd today announced that the U.S. Food and Drug Administration (FDA) cleared their Stimpod NMS460. With the U.S. patent awarded on proprietary hybrid pulsed radio frequency ...